News for 'drug manufacturing'

India offers to make Aids drugs in Africa

India offers to make Aids drugs in Africa

Rediff.com21 Mar 2006

By setting up a unit in a Least Developed Countries, India could take advantage of 'Trips Declaration' in the WTO that allows LDCs to produce generic drugs up to 2016 at a cheaper cost to address public health concerns.

Vasundhara Raje Fading Away Into Oblivion?

Vasundhara Raje Fading Away Into Oblivion?

Rediff.com25 Oct 2023

Vasundhara Raje may have had her faults but she is an unconventional and brave leader who deserves better, observes Aditi Phadnis.

Review: Iru Mugan is a let down

Review: Iru Mugan is a let down

Rediff.com8 Sep 2016

The narrative lacks intensity and pace and unfolds rather blandly, feels S Saraswathi.

J&J seeks permission for trial of 1-shot Covid vaccine in India

J&J seeks permission for trial of 1-shot Covid vaccine in India

Rediff.com20 Apr 2021

The US Food and Drug Administration had in February approved Johnson & Johnson's COVID-19 vaccine that works with just one dose for emergency use.

Serum's Covid vaccine, Covovax, recommended for approval

Serum's Covid vaccine, Covovax, recommended for approval

Rediff.com27 Dec 2021

The Pune-based firm had submitted interim safety and immunogenicity data of phase 2/3 bridging clinical trial conducted in the country as well as interim clinical trial data of safety and efficacy from phase3 clinical trials conducted in the UK and the US along with its application.

FY24 earnings makeover: IndianOil to MRF, companies rewrite profit playbook

FY24 earnings makeover: IndianOil to MRF, companies rewrite profit playbook

Rediff.com6 Dec 2023

The headline for corporate profit growth has been very encouraging in the July-September quarter (Q2) of 2023-24 (FY24), with the combined net profit of listed companies up by 38 per cent year-on-year. However, the earnings distribution has been very lopsided, with most of the growth coming from public-sector oil-marketing companies (OMCs), banks, non-bank lenders, automobile (auto) companies, and cement producers. By comparison, companies from information technology services, fast-moving consumer goods (FMCG), retail, and consumer durables were disappointed, experiencing a sharp slowdown in net sales growth and a relatively muted increase in reported net profit.

Mandaviya meets Dr Reddy's Lab chief on Sputnik V production

Mandaviya meets Dr Reddy's Lab chief on Sputnik V production

Rediff.com5 Aug 2021

Dr Reddy's, which has tied up with Russian Direct Investment Fund for Sputnik V in India, soft launched the vaccine in India in May 2021, after receiving Emergency Use Authorisation in April 2021.

'Maligning the medical fraternity was not expected of PM'

'Maligning the medical fraternity was not expected of PM'

Rediff.com22 Apr 2018

The Indian Medical Association and the Mumbai Association of Medical Consultant have written a letter to Narendra Modi expressing disappointment over his statement during the Bharat ki Baat Sabke saath event in London.

Cadila launches Remdesivir in India at Rs 2,800 per vial

Cadila launches Remdesivir in India at Rs 2,800 per vial

Rediff.com13 Aug 2020

The company said the drug will be made available across India through the group's strong distribution chain reaching out to government and private hospitals treating COVID-19 patients.

Toxins in cough syrups, other drugs due to plastic bottling

Toxins in cough syrups, other drugs due to plastic bottling

Rediff.com1 Jun 2016

Popular antacid Mucaine Gel, manufactured by Pfizer's subsidiary Wyeth Laboratories, was also found laced with the heavy metals as well as cadmium.

Drug abuse on the rise in India: UN report

Drug abuse on the rise in India: UN report

Rediff.com1 Mar 2007

"Many of the pharmaceutical preparations subject to abuse are manufactured in India," affecting all sections of the population, the report stated.

3 Indian pharma firms named in US Congress price probe

3 Indian pharma firms named in US Congress price probe

Rediff.com9 Oct 2014

Details on prices sought as 10 generic drugs become up to 83 times costlier in 6 months

Sputnik V production begins in India; 100mn jabs to be manufactured per year

Sputnik V production begins in India; 100mn jabs to be manufactured per year

Rediff.com24 May 2021

Domestic pharma major Panacea Biotec in collaboration with Russian sovereign wealth fund Russian Direct Investment Fund (RDIF) has begun the production of 'Sputnik V' COVID-19 vaccine in India, according to a joint statement issued.

Maria Sharapova appeals against two-year doping ban

Maria Sharapova appeals against two-year doping ban

Rediff.com14 Jun 2016

Five-times grand slam champion Maria Sharapova is seeking to have her two-year doping ban wiped out or reduced as she lodged an appeal with the Court of Arbitration for Sport (CAS) on Tuesday.

50 million doses of Covaxin set to expire in 2023

50 million doses of Covaxin set to expire in 2023

Rediff.com6 Nov 2022

Nearly 50 million doses of Bharat Biotech's COVID-19 vaccine, Covaxin lying with the firm are set to expire early next year as there are no takers owing to poor demand, company sources said.

Israel trade with India doubled after Covid-19 pandemic

Israel trade with India doubled after Covid-19 pandemic

Rediff.com16 Oct 2023

India's trade ties with Israel have only strengthened in the years after 2019. The total value of trade rose to $10.5 billion on a rolling four-quarter basis in June 2023 from $5.5 billion in the same month in 2019, shows a Business Standard analysis of data from the Centre for Monitoring Indian Economy (CMIE). A rolling four-quarter number provides a comparable figure across different time periods.

Pharma export body suspends Marion Biotech for no reply on syrup deaths

Pharma export body suspends Marion Biotech for no reply on syrup deaths

Rediff.com30 Dec 2022

The drug maker will lose some incentives if its membership is suspended, sources in Pharmexcil said.

Parents sue for girls' deaths due to Covid vaccine; not liable, says govt

Parents sue for girls' deaths due to Covid vaccine; not liable, says govt

Rediff.com29 Nov 2022

The government cannot be held liable to compensate for the deaths due to an adverse event following immunisation (AEFI) post administration of Covid-19 vaccines, the Centre has told the Supreme Court.

Covishield, Covaxin get regular market approval

Covishield, Covaxin get regular market approval

Rediff.com27 Jan 2022

Under the conditions, the firms shall submit data of ongoing clinical trials and the vaccines to be supplied for programmatic setting.Adverse event following immunisation will continue to be monitored.

K'taka election seizures hit Rs 375 cr, sees 4.5 times surge from last polls

K'taka election seizures hit Rs 375 cr, sees 4.5 times surge from last polls

Rediff.com9 May 2023

It said that increased focus on expenditure monitoring was the reason being the seizures, which included freebies such as sarees, 'food kits', pressure cookers and kitchen appliances.

Govt caps trade margin on oxygen concentrators at 70%

Govt caps trade margin on oxygen concentrators at 70%

Rediff.com4 Jun 2021

The government has capped the trade margin on oxygen concentrators at 70 per cent in order to keep in check the price of the much in demand critical life saving component amid the second wave of the coronavirus pandemic. The trade margin has been capped at 70 per cent on price to distributor level on oxygen concentrators. In an official release, the chemicals and fertilisers ministry said the decision has been taken in view of the extraordinary circumstances arising due to the pandemic which has resulted in volatility in Maximum Retail Prices (MRP) of oxygen concentrators.

Drug shortage likely as chemists run on limited stock

Drug shortage likely as chemists run on limited stock

Rediff.com8 Jun 2013

There may be shortage of drugs till pharmaceutical companies supply new batches with revised MRPs.

Trade margins capped at 70% for oximeters, BP meters, other medical devices

Trade margins capped at 70% for oximeters, BP meters, other medical devices

Rediff.com14 Jul 2021

The medical devices, which have been in high demand during the Covid-19 pandemic, will now see a drop in prices, as the earlier margins were up to 709 per cent for some of these products.

Cipla ready to partner in Covid vaccine distribution

Cipla ready to partner in Covid vaccine distribution

Rediff.com17 May 2021

However, Cipla was very clear it does not want to get into vaccine manufacturing.

What is the future of e-pharmacies in India?

What is the future of e-pharmacies in India?

Rediff.com19 Dec 2019

PharmEasy, 1mg and Netmeds believe that their disruptive capabilities will power their brands despite the recent court ruling. The Drug Controller General of India recently directed all state FDAs to stop the online sale of medicines as per a Delhi high court order of last year.

Made in India Sputnik V to be available during Sept-Oct: Dr Reddy's

Made in India Sputnik V to be available during Sept-Oct: Dr Reddy's

Rediff.com27 Jul 2021

Dr Reddy's Laboratories Ltd expects the locally manufactured Russia's COVID-19 vaccine Sputnik V to be available from September-October period, a senior official of the city-based drug maker said.

Govt expects speedy launch of single-dose Sputnik Light vaccine

Govt expects speedy launch of single-dose Sputnik Light vaccine

Rediff.com27 May 2021

The government is hopeful of a speedy launch of single-dose COVID-19 vaccine Sputnik Light in India and all stakeholders, including the Russian manufacturer and its Indian partners, have been directed to fast-track the application and regulatory approval procedures for the jab to boost the country's vaccination drive, sources said.

Cipla gets nod to import Moderna vaccine for emergency use in India

Cipla gets nod to import Moderna vaccine for emergency use in India

Rediff.com29 Jun 2021

India's drug regulator Drugs Controller General of India has granted permission to Mumbai-based pharmaceutical company Cipla to import Moderna's COVID-19 vaccine for restricted emergency use in the country, official sources said on Tuesday.

Focus on hospitals as India braces for Covid third wave

Focus on hospitals as India braces for Covid third wave

Rediff.com1 Sep 2021

The health system is trying to ensure that it isn't caught by surprise -- the way it was last time. So, hectic preparations are on.

Sun Pharma, Dr Reddy's price scrutiny in US reaches next level

Sun Pharma, Dr Reddy's price scrutiny in US reaches next level

Rediff.com21 Oct 2014

On October 2, a legislature committee wrote letters to the 14 companies, initiating an investigation and seeking details about recent price increases in several generic products available in the American market.

How India Can Rival China As Production Platform

How India Can Rival China As Production Platform

Rediff.com28 Jul 2023

We have the workforce, now we need to ensure that we take full advantage of game-changing technologies and geopolitical openings, suggests Jayant Sinha, chairman, Parliament's Standing Committee on Finance.

WHO clears Serum Institute's Covovax for emergency use

WHO clears Serum Institute's Covovax for emergency use

Rediff.com18 Dec 2021

'WHO issued an emergency use listing for Covovax, expanding the basket of WHO-validated vaccines against COVID-19. The vaccine is produced by the Serum Institute of India under licence from Novavax,' the world health body said in a tweet on Friday.

Unfazed by legal blocks, Netmeds bets big on digital

Unfazed by legal blocks, Netmeds bets big on digital

Rediff.com8 Feb 2019

Netmeds is looking at using new technologies such as deep learning and data analytics to improve forecasting in terms of the demand of the products for pharma companies, reports Peerzada Abrar.

Govt ramps up Remdesivir production to 74 lakh vials

Govt ramps up Remdesivir production to 74 lakh vials

Rediff.com23 Apr 2021

The Union home ministry said several steps have been taken to augment the production and supply of Remdesivir injections from 38.80 lakh units per month to 74 lakh units per month by early next month, and asked the states to ensure its seamless supply and transport.

3rd wave: Govt creating 30-day stock of key Covid medicines

3rd wave: Govt creating 30-day stock of key Covid medicines

Rediff.com26 Jul 2021

'The Centre is planning to procure five million vials of Remdesivir ahead of the third wave. What's better is that this time, the government is paying us in advance,' said a senior executive of a Mumbai-based pharma player which makes Remdesivir. Sohini Das reports.

Himalaya Drug to build R&D unit near Bangalore

Himalaya Drug to build R&D unit near Bangalore

Rediff.com27 May 2003

Himalaya Drug Company said on Tuesday that it is setting up a Rs 165 crore (Rs 1.65 billion) research and development and manufacturing unit on the outskirts of Bangalore to be completed by 2005.

Hard choice for MSME med device makers: Get licence by Oct 1 or shut shop

Hard choice for MSME med device makers: Get licence by Oct 1 or shut shop

Rediff.com27 Sep 2022

The transition of Class A and Class B medical device makers to the licensing regime by October 1 seems to be an uphill task with several small and medium manufacturers saying they are still awaiting the audit from the government authorities. If the licenses don't come through, either due to lack of audits or MSME units not clearing the audits, then a few thousand small-scale medical device units will face the issue of business continuity in three weeks. Class A medical devices are those with low to moderate risk to the patient or user (surgical dressings for example), while Class B medical devices refer to devices with moderate risks that require special controls (catheters for example).

Dr Reddy's soft-launches Sputnik V in India at Rs 995 per dose

Dr Reddy's soft-launches Sputnik V in India at Rs 995 per dose

Rediff.com15 May 2021

Dr Reddy's Laboratories on Friday soft-launched imported COVID-19 vaccine Sputnik V, with Deepak Sapra, a senior executive of the drug-maker, taking the first shot in Hyderabad.

Govt denies pressuring Covaxin makers for early release of vaccine

Govt denies pressuring Covaxin makers for early release of vaccine

Rediff.com17 Nov 2022

The Union health ministry on Thursday termed as 'misleading' and 'fallacious' media reports which claimed that regulatory approval for COVID-19 vaccine Covaxin was rushed due to political pressure.